INDIANAPOLIS, Oct. 29 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas® 8000 modular analyzer ...

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the cobas® 8000 modular analyzer series, a Serum Work Area solution ...

With the introduction of the cobas 8000 modular analyzer series, Roche now offers a comprehensive portfolio of standardized integrated systems to meet the needs of all types and sizes of clinical ...

Swiss biotech company Roche announced on December 21, 2015 that the FDA has approved the Cobas® 6800 and 8800 Systems from its Pleasanton, California-based Roche Molecular Diagnostics (RMD) for ...

Roche announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas 8000 modular analyzer series for diagnostic labs with high-volume workloads. Labs will now ...

The track system consists of two cobas 8000 platforms (one with two cobas c 701 chemistry modules and two cobas e 602 immunoassay modules and the other with one cobas c 701 and two cobas e 602 modules ...

The cobas 8000 series is the newest member of the Roche cobas modular platform family, which combines clinical chemistry and immunochemistry testing. With a peak throughput of up to 9,800 tests ...